Identification of factors associated with first-cycle drug approval rates and regulatory outcomes for new drug applications
| Autor: | Margaret Vanheusen, Lin-Chau Chang, Christopher D. Breder, Xiao Fang |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
0301 basic medicine
Pharmacology Drug medicine.medical_specialty United States Food and Drug Administration business.industry media_common.quotation_subject Public health Approval rate United States Unmet needs 03 medical and health sciences Identification (information) 030104 developmental biology 0302 clinical medicine 030220 oncology & carcinogenesis Family medicine Drug approval medicine business Drug Approval media_common |
| Zdroj: | Pharmacological Research. 139:166-172 |
| ISSN: | 1043-6618 |
| Popis: | The aims of this study were to identify types of deficiencies resulting in delay of approvals for drugs eventually approved by the US FDA and to search for factors associated with higher first-cycle approval rates. Review documents of New Drug Applications approved between 2008 and 2017 were retrieved from the Drugs@FDA database. Basic characteristics of the applications, regulatory actions, and reasons for non-approvals and/or major amendments after first review cycle were investigated. Of 825 applications studied, 446 (54.1%) applications received first-cycle approvals without a review extension resulting from a major amendment. Non-approvals (240, 29.1%) were based primarily on chemistry/manufacturing/controls and safety reasons. A higher first-cycle approval rate was associated with factors related to unmet medical needs or innovative development. The association between higher first-cycle approval rates and innovative drugs or those addressing unmet needs reveals the FDA’s commitment in advancing innovation and protecting public health. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect